Literature DB >> 23811418

First do no harm--adverse events, drug intolerance, and hepatotoxicity: how can we not justify directly observed therapy for treating tuberculosis?

Barbara J Seaworth1, Lisa Y Armitige, David E Griffith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23811418     DOI： 10.1093/cid/cit432

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  Reply to Moonan and Weis, Seaworth et al, and Nunn and Phillips.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2013-06-27       Impact factor: 9.079

2.  Fostering directly observed treatment in tuberculosis: a program manager's perspective.

Authors:  Saurabh Rambiharilal Shrivastava; Prateek Saurabh Shrivastava; Jegadeesh Ramasamy
Journal:  Int J Health Policy Manag       Date:  2013-12-05

Review 3.  Directly observed therapy for treating tuberculosis.

Authors:  Jamlick Karumbi; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-29

4.  An attempt to reproduce a previous meta-analysis and a new analysis regarding the impact of directly observed therapy on tuberculosis treatment outcomes.

Authors:  Brian McKay; Maria Castellanos; Mark Ebell; Christopher C Whalen; Andreas Handel
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

5.  Direct Observation of Treatment Provided by a Family Member as Compared to Non-Family Member among Children with New Tuberculosis: A Pragmatic, Non-Inferiority, Cluster-Randomized Trial in Gujarat, India.

Authors:  Paresh Vamanrao Dave; Amar Niranjan Shah; Pankaj B Nimavat; Bhavesh B Modi; Kirit R Pujara; Pradip Patel; Keshabhai Mehariya; Kiran Vaman Rade; Soma Shekar; Kuldeep S Sachdeva; John E Oeltmann; Ajay M V Kumar
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

Review 6.  Tuberculosis treatment.

Authors:  Marcelo Fouad Rabahi; José Laerte Rodrigues da Silva Júnior; Anna Carolina Galvão Ferreira; Daniela Graner Schuwartz Tannus-Silva; Marcus Barreto Conde
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.